Cure My Disease

Don't miss your cure!

 Log in / Sign up

Biobank aims to crack the code of rare movement disorders

NCT ID NCT07838883

Knowledge-focused Sponsor: First Affiliated Hospital of Wannan Medical College Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers in southern Anhui are building a registry and biobank for four rare inherited movement disorders: motor neuron diseases, spinocerebellar ataxias, hereditary muscular dystrophy, and hereditary spastic paraplegia. Adults with a confirmed diagnosis can join. The study collects clinical scores, such as walking distance and ataxia ratings, along with biological samples. The goal is to gather reliable data on risk factors and early diagnosis to support future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry succeeds, it could give researchers the data and biological samples they need to spot early signs of these diseases and design future treatment trials.
What could go wrong
A registry only collects information, so it will not treat anyone or produce a cure by itself. Findings may take years and may not apply to patients outside this region.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

These rare movement-related neurological diseases are all characterized primarily by gait abnormalities; although muscle weakness, ataxia, poor muscle endurance, and spastic paraplegia are their typical presentations, respectively, they share overlapping motor neurological symptoms and similar early clinical manifestations.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 19 years or older who are capable of giving informed consent. * Definitive diagnosis of one of the following diseases: (1) amyotrophic lateral sclerosis (diagnosed according to the revised El Escorial criteria, Awaji criteria, or Gold Coast criteria); (2) spinocerebellar ataxia; (3) muscular dystrophy; (4) hereditary spastic paraplegia. * Others: primary lateral sclerosis, progressive muscular atrophy, ALS-FTD syndrome, progressive bulbar palsy, benign focal muscular atrophy, and other motor neuron diseases. Exclusion Criteria: * Patients with concomitant systemic diseases; * Vulnerable research subjects: minors and patients with cognitive impairment; * Participants from whom clinical information and human biological samples cannot be collected; * Other patients judged by the investigators to be unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis autosomal dominant cerebellar ataxia cerebellar ataxia frontotemporal dementia with motor neuron disease hereditary spastic paraplegia lateral sclerosis monomelic amyotrophy motor neuron disorder muscular dystrophy progressive bulbar palsy progressive muscular atrophy Spinocerebellar Ataxias

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary muscular dystrophy Hereditary spastic paraplegia Motor neuron diseases Spinocerebellar ataxias

Contacts and locations

Locations

  • First affiliated hospital of Wannan Medical University

    Wuhu, Anhui, 241001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.